Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

被引:9
作者
Hernandez-Espinosa, David [1 ]
Minano, Antonia [1 ]
Martinez, Constantino [1 ]
Ordonez, Adriana [1 ]
Perez-Ceballos, Elena [1 ]
de Arriba, Felipe [1 ]
Mota, Ruben A. [2 ]
Ferrer, Francisca [1 ]
Gonzalez, Marcos [3 ]
Vicente, Vicente
Corral, Javier [1 ]
机构
[1] Univ Salamanca, Hosp Clin, Hematol Serv, Salamanca 30003, Spain
[2] Ctr Reg Hemodona, Dept Med, Murcia, Spain
[3] Univ Murcia, Dept Biochem Mol Biol B & Immunol, E-30001 Murcia, Spain
关键词
proteasome inhibitors; bortezomib; serpin; heat-shock proteins; conformation; aggregation;
D O I
10.1038/labinvest.3700717
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Conformational diseases include heterogeneous disorders sharing a similar pathological mechanism, leading to intracellular aggregation of proteins with toxic effects. Serpins are commonly involved in these diseases. These are structurally sensitive molecules that modify their folding under even minor genetic or environmental variations. Indeed, under normal conditions, the rate of misfolding of serpins is high and unfolded serpins must be degraded by the proteasome system. Our aim was to study the effects of bortezomib, a proteasome inhibitor, on conformationally sensitive serpins. The effects of bortezomib were analysed in patients with multiple myeloma, HepG2 cells, and Swiss mice, as well as in vitro. Levels, anti-FXa activity, heparin affinity, and conformational features of antithrombin, a relevant anticoagulant serpin, were analysed. Histological, ultrastructural features and immunohistological distribution of antithrombin and alpha 1-antitrypsin (another hepatic serpin) were evaluated. We also studied the intracellular accumulation of conformationally sensitive (fibrinogen) or non-sensitive (prothrombin) hepatic proteins. The inhibition of the proteasome caused intracellular accumulation and aggregation of serpins within the endoplasmic reticulum that was associated with confronting cisternae and Mallory body formation. These effects were accompanied by a heat stress response. Bortezomib also increased the levels of intracellular fibrinogen, but has no significant effect on prothrombin. Finally, bortezomib had only minor effects on the mature circulating antithrombin, with increased amounts of latent antithrombin in plasma. These results suggest that the impairment of proteasomal activities leads to an intracellular accumulation of conformationally sensitive proteins and might facilitate the release of misfolded serpins into circulation where they adopt more stable conformations.
引用
收藏
页码:306 / 317
页数:12
相关论文
共 51 条
[1]   The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation [J].
Bardag-Gorce, F ;
Riley, NE ;
Nan, L ;
Montgomery, RO ;
Li, J ;
French, BA ;
Lue, YH ;
French, SW .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2004, 76 (01) :9-16
[2]   Antithrombins Wibble and Wobble (T85M/K): Archetypal conformational diseases with in vivo latent - Transition, thrombosis, and heparin activation [J].
Beauchamp, NJ ;
Pike, RN ;
Daly, M ;
Butler, L ;
Makris, M ;
Dafforn, TR ;
Zhou, A ;
Fitton, HL ;
Preston, FE ;
Peake, IR ;
Carrell, RW .
BLOOD, 1998, 92 (08) :2696-2706
[3]  
Braun A, 1996, EUR J CLIN CHEM CLIN, V34, P761
[4]   THROMBOEMBOLIC DISEASE DUE TO THERMOLABILE CONFORMATIONAL-CHANGES OF ANTITHROMBIN ROUEN-VI (187-ASN-]ASP) [J].
BRUCE, D ;
PERRY, DJ ;
BORG, JY ;
CARRELL, RW ;
WARDELL, MR .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2265-2274
[5]  
Bush KT, 1997, J BIOL CHEM, V272, P9086
[6]   Conformational disease [J].
Carrell, RW ;
Lomas, DA .
LANCET, 1997, 350 (9071) :134-138
[7]   Cell toxicity and conformational disease [J].
Carrell, RW .
TRENDS IN CELL BIOLOGY, 2005, 15 (11) :574-580
[8]   How serpins change their fold for better and for worse [J].
Carrell, RW ;
Huntington, JA .
PROTEASES AND THE REGULATION OF BIOLOGICAL PROCESSES, 2003, 70 :163-178
[9]   Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting [J].
Ciechanover, A .
CELL DEATH AND DIFFERENTIATION, 2005, 12 (09) :1178-1190
[10]  
Corral J, 2005, HAEMATOLOGICA, V90, P238